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Abstract: Long considered vital to antioxidant defenses, thiol chemistry has more recently
been recognized to be of fundamental importance to cell signaling. S-nitrosothiols—such as
S-nitrosoglutathione (GSNO)—and hydrogen sulfide (H2S) are physiologic signaling thiols that
are regulated enzymatically. Current evidence suggests that they modify target protein function
primarily through post-translational modifications. GSNO is made by NOS and other metalloproteins;
H2S by metabolism of cysteine, homocysteine and cystathionine precursors. GSNO generally acts
independently of NO generation and has a variety of gene regulatory, immune modulator, vascular,
respiratory and neuronal effects. Some of this physiology is shared with H2S, though the mechanisms
differ. Recent evidence also suggests that molecules resulting from reactions between GSNO and H2S,
such as thionitrous acid (HSNO), could also have a role in physiology. Taken together, these data
suggest important new potential targets for thiol-based drug development.
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1. Introduction
Thiol chemistry has recently been recognized to be important for the regulation of cell signaling
processes. S-nitrosoglutathione (GSNO) and other S-nitrosothiols, as well as hydrogen sulfide
(H2S), are enzymatically-regulated cell signaling thiols, affecting target protein function through
post-translational modifications. Regulation of the metabolism of GSNO, of other S-nitrosothiols and
of H2S (Figure 1) are vital to immune, vascular, respiratory and neuronal signaling. Here, we will
review data regarding the role and regulation of these molecules in physiology.
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Figure 1. Eukaryotic thiol chemistry and the generation of thiol-based signaling molecules. Orange 
highlight shows product signaling molecules. AKR1A1—aldoketoreductase family 1 member 1A, 
CAT—cysteine aspartate aminotransferase, CBS—cystathionine b-synthase, CSE—cystathionine 
gamma lyase, CDO—cysteine deoxygenase, CoA—Coenzyme A, C-SNO—S-nitrosocysteine, 
GSNO—S-nitrosoglutathione, GSNOR—S-nitrosoglutathione reductase, GS—glutathione synthase, 
GCS—glutamylcysteine synthase, MAT—methionine adenosyltransferase; SAM- S-adenosyl 
methionine; 3MST—3 mercaptopuruvate sulfur transferase, PTA—pantetheinase, SNO-CoA—S-
nitroso-Coenzyme A, γGT—γ-glutamyl transpeptidase. 
2. Overview of S-Nitrosothiol Metabolism  
2.1. Production of S-Nitrosothiols and Other Nitrogen Oxides In Vivo  
Nitric oxide synthases (NOS) use the guanidino nitrogen of l-arginine [1–4] to form NO, and 
GSNO is also often formed when NOS is activated [5–8]. Three principal isoforms of NOS exist [9–
11]. These are neuronal (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). Activation of 
all three can result in downstream S-nitrosothiol formation [6,9,10,12] (Figure). Reactions of NO with 
thiols are typically kinetically favored to occur through interactions with metalloproteins rather than 
through inorganic NO oxidation. Typically, they involve NO oxidation to NO+. NO is oxidized by 
reactions with superoxide and with certain metal ions. NO also reacts with oxygen, but this reaction 
is third order (third order rate constant ~7 × 103 L2 mol–2 sec–1) [13]: The reaction is normally quite 
slow in physiology because the concentrations of NO in the body gas phase are ~nM. The reaction 
rate is favored in membranes [14] because the reactants are more soluble in lipid than water. As 
discussed more below, GSNO and other S-nitrosothiols are typically formed through reactions of NO 
with iron and copper groups in these metalloproteins (including NOSs), though there is evidence 
also for formation of a complex with an amine of NOS-bound tetrahydrobiopterin (BH4) [15] and 
other reactions [16]. Other metalloproteins involved in S-nitrosothiol formation include Hb, where S-
nitrosylation occurs at the b-93 cysteine [17], and ceruloplasmin [18].  
Endothelial NOS provides an example of the role of S-nitrosothiol formation and NO in biology 
[19–21]. We and others have shown that eNOS activation can result in S-nitrosothiol formation 
[12,22]. Moreover, GSNO catabolism by GSNO reductase is required to reverse and or modulate the 
effects of eNOS, suggesting that, in physiology, GSNO is a regulated eNOS product [19,23]. At the 
Figure 1. Eukaryotic thiol chemistry and the generation of thiol-based signaling
molecules. Orange highlight shows product signaling molecules. AKR1A1—aldoketoreductase
family 1 member 1A, CAT—cysteine aspartate aminotransferase, CBS—cystathionine
b-synthase, CSE—cystathionine gamma lyase, CDO—cysteine deoxygenase, CoA—Coenzyme A,
C-SNO—S-nitrosocysteine, GSNO—S-nitrosoglutathione, GSNOR—S-nitrosoglutathione reductase,
GS—glutathione synthase, GCS—glutamylcysteine synthase, MAT—methionine adenosyltransferase;
SAM- S-adenosyl methionine; 3MST—3 mercaptopuruvate sulfur transferase, PTA—pantetheinase,
SNO-CoA—S-nitroso-Coenzyme A, γGT—γ-glutamyl transpeptidase.
2. Overview of S-Nitrosothiol Metabolism
2.1. Production of itrosothiols and Other Nitrogen Oxides In Vivo
Nitric oxide synthases (NOS) use the guanidino nitrogen of l-arginine [1–4] to form NO, and GSNO
is also often formed when NOS is activated [5–8]. Three principal isoforms of NOS exist [9–11].
These are neuronal (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). Activation of all
three can result in downstream S-nitrosothiol formation [6,9,10,12] (Figure 1). Reactions of NO with
thiols are typically kinetically favored to occur through interactions with metalloproteins rather than
through inorganic NO oxidation. Typically, they involve NO oxidation to NO+. NO is oxidized by
reactions with superoxide and with certain metal ions. NO also reacts ith oxygen, but this reaction is
third order (third order rate constant ~7 × 103 L2 mol−2 sec−1) [13]: The reaction is normally quite slow
in physiology because the concentrations of NO in the body gas phase are ~nM. The reaction rate is
favored in membranes [14] because the reactants are more soluble in lipid than water. As discussed
more below, GSNO and other S-nitrosothiols are typically formed through reactions of NO with iron and
copper groups in these etalloproteins (including NOSs), though there is evidence also for formation
of a complex with an amine of NOS-bound tetrahydrobiopterin (BH4) [15] and other reactions [16].
Other metalloproteins involved in S-nitrosothiol formation include Hb, where S-nitrosylation occurs
at the b-93 cysteine [17], and ceruloplasmin [18].
Endothelial NOS provides an example of the role of S-nitrosothiol formation and NO in
biology [19–21]. We and others have shown that eNOS activation can result in S-nitrosothiol
formation [12,22]. Moreover, GSNO catabolism by GSNO reductase is required to reverse and or
modulate the effects of eNOS, suggesting that, in physiology, GSNO is a regulated eNOS product [19,23].
At the myoendothelial junction, eNOS is colocalized with somatic cell hemoglobin alpha [20]. When the
iron of the hemoglobin is oxidized, eNOS activation produces NO and S-nitrosothiols; when it is
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reduced, inert nitrate is formed [22]. Note that impaired activity of eNOS resulting from oxidative
stress in the endothelium involves BH4 oxidation [24,25]. This induces the uncoupling of eNOS,
with consequent generation of O2− instead of NO [24,26] or GSNO [12]. Endothelial NOS redox
chemistry, with products including thiol-stabilized S-nitrosothiols, inert nitrite and nitrate and highly
ONOOH, are relevant to a range of vascular diseases [25–36]
2.2. S-Nitrosylation Signaling and S-Nitrosothiols
Broadly, thiols modified by a NO+ (RS− - NO+), NO− (R-S+-NO−) or NO (RS-NO) are referred to
as S-nitrosothiols [27]. The thiol R group can be a simple proton (thionitrous acid, see below), or can
be an amino acid, peptide or protein. S-Nitrosylation is a normally a targeted, post-translational
protein cysteine modification with a specific biological purpose. Note that S-nitrosylated proteins may
transfer NO to other proteins [28–30]. S-nitrosylation is regulated as a signaling reaction. [5,12,31,32].
Regulation of human airway tone provides an example. GSNO is normally present in the human
airway at ~500 nM (30), the IC50 for soluble guanylate cyclase (sGC)-independent human airway
dilatation [33]. GSNO preventsβ2 agonist tachyphylaxis by S-nitrosylating GRK2 downstream of eNOS
activation through its effect on β arrestin to [19]. Indeed, tachyphylaxis to β2-AR agonists is ablated
in [19,34] mice lacking the ability to reduce GSNO because of deletion of the enzyme, GSNO reductase
(GSNOR). These mice are protected from β-AR [34], and humans with gain-of-function in this enzyme
are at increased asthma risk [35].
There are many additional examples of signaling caused by GSNO and other
S-nitrosothiols [5,6,12,31,32,36]. These molecules regulate a broad range of bioactivities, ranging from
coagulation and N-methyl-d-aspartate (NMDA) dependent neuronal signaling [37,38]. In many cases,
NO+ is transferred from a low-mass S-nitrosothiol to a protein thiol. A recent example involves
S-nitrosylation of connexin 43 (Cx43) hemichannels in the Duchenne Muscular Dystrophy (Dmd) heart
that has been driven by β2 agonists to develop stress-induced arrhythmias: inhibition of NOS prevents
arrhythmias evoked by isoproterenol [39]. NOS activation results in S-nitrosylation of Cx43 at cysteine
271, regulating arrhythmia risk. [39].
Other mechanisms of thiol modification are relevant as well. Myeloperoxidase causes protein
thiol S-nitrosylation at tyrosine-Xn-cysteine (YXnC) motifs in the presence of hydrogen peroxide
and nitrite [16]. Inorganic S-nitrosylation can occur at low pH, particularly in the mitochondrial
intermembrane space [40], in the lung and gut, and in the blood vessels in ischemic tissues [41,42].
In the case of hemoglobin- and ceruloplasmin-mediated S-nitrosylation, NO radical normally first
reduces the metal: Fe3+-NO transitions to Fe2+-NO+; Cu2+- NO transitions to Cu+-NO+. Of note,
GSNO can serve as an intermediate to transfer the NO+ equivalent from a metalloprotein to a
target thiolate.
Note that the GSNO breakdown product, S-nitroso-L-cysteine (L-CSNO), is increasingly
appreciated as a stereoselective signaling molecule. L-CSNO was originally considered an endothelium
derived relaxing factor (EDRF) [43–46]. Lewis, Bates and others observed that the L-isomers of
CSNO and related S-nitrosothiols were substantially more active than the D-isomers, though they
evolve NO equally [47–49]. Their findings suggest that L-CSNO activates stereoselective recognition
sites [50]. In guinea-pig myocytes, L-CSNO activates large conductance Ca2+ activated K+-channels
by S-nitrosylation of the alpha subunit [51]. In porcine coronary arteries, L-CSNO activates
intermediate and small conductance Ca2+-activated K+-channels. S-nitroso-D-cysteine (D-CSNO) does
not have these effects [45,46]. Ca2+-activated K+-channels activation causes vasorelaxation exclusively
from voltage-gated Ca2+ channel closures induced by hyperpolarization [52]. Though nifedipine,
a voltage-gated Ca2+ +channel blocker, reduces vasodilator responses from donors of NO, it does not
reduce the responses of L-CSNO or the release of EDRF by acetylcholine [52].
Signaling mediated by S-nitrosothiols is not unique to mammalian physiology: it is vital in
plant biology and in microbiology. Interaction between eukaryotic host and its microbiome has
been shown to be affected by inter-species S-nitrosothiol signaling [53]. For example, prokaryotic
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S-nitrosothiol signaling uses the hybrid-cluster protein Hcp downstream of nitrate reductase. Here,
the complex interactions of S-nitrosothiol synthases and transnitrosylases signal E. Coli mobility and
metabolism [36].
2.3. Denitrosylation
Like other post-translational modifications, S-nitrosylation signaling is balanced by the reverse
effect, denitrosylation. Many enzymes function as denitrosylases. Commonly, these use NAD(P)H
oxidation to reduce S-nitrosothiols. Examples include NADH-dependent GSNO reductase (see below)
and NADPH-dependent SNO-Coenzyme A reductase (Figure 1). Many additional enzyme systems
catabolize GSNO, the details of which are beyond the scope of this review [54–60] Products can include
another S-nitrosothiols, NO, ONOOH, NH2OH and NH3. SNO-CoA reductase is also known as
aldo-keto reductase family 1 member A1 (AKR1A1) (Figure 1). AKR1A1 can catabolize both SNO-CoA
and GSNO [61].
These S-nitrosothiol catabolic enzymes play critical roles in human physiology. For example,
GSNOR gene variants affect asthma prevalence and β2 agonist responsiveness in specific human
asthma subpopulations [35,62,63]; we have identified a specific severe asthmatic population phenotype
associated with high GSNOR activity [64]. Denitrosylation functions are vital, as evidenced by
functional redundancy. For example, GSNOR -/- mice have more AKR1A1 GSNO catabolic activity
than do wild type mice [61].
3. Hydrogen Sulfide Production and Metabolism In Vivo. Similarities and Differences of NO and
H2S Metabolism
Like GSNO, H2S is a thiol-based mediator that is produced enzymatically and is active in
physiology at low, endogenous concentrations [65–67]. Hydrogen sulfide is produced by mammalian
enzymes cystathione-lyase(CSE), cystathione-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase
(3-MST) [68]. Additionally, cysteine aminotransferase (CAT) produces 3-mercaptopyruvate substrate
for 3MST to produce a protein-bound persulfide, that in turn can be reduced to form H2S [69,70]
(Figure 1), and, in plants, by desulfhydrases [71]. Note that CBS and CSE are multifunctional enzymes
catalyzing a range of β replacement and α, β and γ elimination reactions: Their roles in thiol chemistry
can often be redundant (Figure 1). The substrate for 3MST is 3-mercaptopyruvate; others can use
L-cysteine, cystathione and other substrates (Figure 1).
As with S-nitrosothiol-based signaling, H2S can affect physiology by causing post-translational
modifications of protein thiols. Also as with S-nitrosothiols, specific enzymes also break down
H2S [72]. For example, mitochondrial rhodanese, a sulfur transferase, catalyzes H2S oxidation [73], as a
component of a major H2S catabolic pathway that also involves a sulfide quinone oxido-reductase (SQR)
and a sulfur dioxygenase. H2S catabolic enzymes are extensively reviewed in ref [74]. Additionally,
iron-containing proteins, such as hemoglobin and cytochrome C oxidase, also can serve as sinks for
H2S (71,77).
The first physiological protein target identified for H2S involved vasodilatation mediated by
H2S modification of the K ATP (Kir6.x) channel [75]. Like S-nitrosothiols, H2S also acts through
post-translational modifications of protein. The key reaction is defined as S-sulfhydration [76,77],
the forming protein –SSH moieties. This S-sulfhydration reactions can modify a large
number of proteins, including GAPDH (at Cys150), albumin, actin, ADH1, AST, catalase and
thioredoxin-reductase [76]. Indeed, there could well be cross-talk between S-nitrosylation and
S-sulfhydration signaling [78].
Inhibition of NOS by the nonspecific inhibitor L-NAME leads to inhibition of H2S-induced
vasodilation [79–81], while the deletion of CSE (cystathionine γ-lyase) enhances the vasodilatory effects
of acetylcholine [82].
Like S-nitrosothiols, H2S signaling has a role in regulating vascular tone. CSE−/− mice have
increased blood pressure as they age [83]. Isolated vessels from CSE−/− mice have significantly
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impaired methacholine-induced vasodilatation. Of note, activation of endothelial CSE and eNOS
are both Ca2+-calmodulin dependent [83,84]; and both can involve cGMP and phosphodiesterases,
with competing effects. [85,86].
In contrast to some of the more labile S-nitrosothiols; however, H2S is relatively stable in certain
body compartments. However, it can be metabolized by methylation or oxidation, and its products
excreted in urine [87,88]. It is also is scavenged by its reactions with heme. H2S for example,
because of its interaction with mitochondrial cytochrome c oxidase [67,89], can be toxic at higher
concentrations [90,91]. Two H2S oxidative pathways have been identified recently and involve cytosolic
ferric (met) hemoglobin (Hb) in red blood cells [92] and myoglobin (Mb) in the heart [93]. Both of these
proteins have the capability to generate heme-bound polysulfides and free thiosulfates as end-products.
Decreasing pH (across the range 8–6.8) decreases heme H2S-affinity by causing a right-shift in the
binding of H2S to metHb. Equilibrium dissociation constants of metHb and H2S are in the range of
0.26–1.08 µM, which is well below that for NO it (~100 µM) [94] and CN−(~10 µM) [95], among other
metHb ligands. This indicated that H2S is a high-affinity metHb ligand. Rate constants for metHb
(3.2 × 103M−1s−1) [37] and metMb (1.6 × 104M−1s−1) [96] suggest that metHb is a reversible H2S carrier,
affecting H2S bioactivities [95].
Thionitrous Acid and Related Compounds
Thionitrous acid (HSNO) is another low molecular weight thiol that may be relevant to signaling.
HSNO can be formed by reactions between hydrogen sulfide (H2S) and S-nitrosothiols [97–99].
For example, HSNO is produced rapidly according to, H2S + GSNO→HSNO + GSH. Theoretically,
HSNO can also be formed by the reaction N2O3→HSNO + HNO2. However, as noted above, N2O3 is
not formed abundantly in most physiological systems.
It has been shown that the NaHS/GSNO reaction products relax precontracted rat aortic rings with
pharmacology consistent with the relevance of HSNO or SNO-intermediates. These are dependent on
heme concentrations, as well as pH [100]. Of note, there is evidence that HSNO can diffuse through
membranes to signal in physiology [98], supporting a possible role as a signaling molecule. Note,
however, that the pKa of HSNO is low, and HSNO in physiology may exist as the SNO− anion.
A molecule, QT490, has been developed that forms HSNO and provides insight into formation of
HSNO/RSNO from the reaction between H2S/RSH and NO in the biological system [101].
It is also possible that HNO and HSSH could be formed from HSNO with H2S. The resulting
S–N bond is the longest reported S–N bond for an R-SNO compound, 1.84 Å [102]. The tautomeric
form of HSNO is more thermodynamically feasible and kinetically accessible [103]. These reactions
could also form bioactive nitroxyl HNO [103]. HNO is a powerful vasodilator. While NO reacts slowly
with thiols, the reaction of HNO with thiols is very fast and it depends on the pKa of the reacting
thiolate [104]. Rapid HNO production can also occur in small-to-medium-sized sensory neurons and
axons, where it was observed to be co-expression of CBS (cystathionine beta synthase) with TRPA1
(transient receptor potential channel A1) [79]. TRPA1 is the Ca2+ ion channel responsible for CGRP
release induced by HNO), [79] which is known to be co-expressed with nNOS. Reactive cysteine
residues on TRPA1 become oxidized by HNO, resulting in long-lasting channel opening, Ca2+ influx,
and subsequent release of CGRP [105]. These three proteins, CBS, nNOS, and TRPA1, represent a
functional unit that is involved in the regulation of peripheral blood flow [106] and even the regulation
of systemic blood pressure [79] It has been hypothesized that the disturbances in the regulation of this
pathway might be responsible for the migraine attacks [106].
Taken together, these data suggest the possible relevance of HSNO at the interface of S-nitrosothiol
and H2S signaling.
4. Conclusions
Small thiol molecules have cell signaling effects in physiological concentrations.
Both S-nitrosothiols and H2S can be formed and broken down by specific regulatory proteins.
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Both have physiological effects involving post-translational modifications, primarily at cysteine
residues, but the mechanisms are different. Once considered primarily valuable for breaking disulfide
bods to reduce viscosity and/or to augment antioxidant defenses, thiol chemistry is beginning to be
recognized as relevant to cell signaling reactions. These recent observations suggest that thiol chemistry
may be more useful than previously thought for new drug development.
However, more work needs to be done to understand in greater details the roles of S-nitrosothiols
and of H2S in physiology, and to determine the degree to which HSNO chemistry is relevant to biology.
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